2026 · Devices & clinical
X-Factor: Antithrombotic Coating Reduces Procedural Thromboembolic Events in Flow Redirection Endoluminal Device (FRED) Aneurysm Embolization
Snyder MH, Dincer A, Yu AJ, Burke SM, Ferraro T, Malek AM.
World Neurosurg 205:124723, 2026.
PMID 41391599 · DOI 10.1016/j.wneu.2025.124723
Narrated summary
Figures from the open access article (CC BY 4.0).
Read the transcript
Here's a short summary of our recent study from our team at Tufts Medical Center, comparing two versions of a flow diverter. I'm Adel Malek. Many brain aneurysms are now treated with a flow diverter: a fine mesh tube placed inside the artery across the aneurysm's neck. It steers blood past the aneurysm, which slowly clots off and heals. But a metal mesh inside a blood vessel can trigger clots of its own. Even with blood-thinning medication, small clots can form on the device during the procedure and slow or block small branches.
The FRED is a flow diverter with two layers: a dense inner mesh and an outer supporting braid. Its newer version, FRED X, adds a coating bonded to the metal surface, designed to make it less likely to form clots. We reviewed our center's cases: 19 procedures with the original FRED and 37 with FRED X. All patients had confirmed platelet inhibition before treatment. We looked for clots on the angiogram during the procedure, and for small spots of injury on MRI afterward.
With the original FRED, clots formed during 7 of 19 procedures, about 37 percent. In each case, medication given directly into the artery dissolved the clot, and no patient had stroke symptoms. With FRED X, there were none: zero clots in 37 procedures. When we combined clots during the procedure with small spots on MRI afterward, events fell from 58 percent with FRED to just under 14 percent with FRED X. The device type remained significant after accounting for age, sex, and platelet testing.
This surface treatment may make these procedures safer by preventing clots from forming on the device. Larger studies will help confirm it.
In plain language
The FRED is a flow diverter, a fine mesh tube placed inside an artery to steer blood away from an aneurysm. Metal devices can trigger blood clots, so a newer version, FRED X, has a surface coating meant to reduce clotting.

This single-center study compared 19 procedures with the original FRED and 37 with FRED X. Clots seen on imaging during the procedure occurred in 7 of 19 (36.8%) FRED cases and none of the FRED X cases, and all were successfully dissolved with medication without symptoms. A combined measure of clot-related events, including small spots on MRI after the procedure, occurred in 57.9% with FRED and 13.5% with FRED X.
The coating may lower the risk of clots during treatment.
A plain-language summary for patients and families. It is not medical advice, and individual results vary.
Abstract
Background
The Flow Redirection Endoluminal Device (FRED) is a dual-layer flow diverting stent with a dense inner mesh and outer braided support providing superior deployment control. Covalently bonded Poly(2-methoxyethyl acrylate) X coating was introduced to decrease metal-induced thrombogenicity in the newer FRED X variant. The objective of the current study is to evaluate procedural thromboembolic events associated with both variants.
Methods
A single-center retrospective analysis was undertaken comparing angiographically detected intraprocedural thromboembolic events, postprocedural magnetic resonance diffusion weighted imaging lesions (MR-DWI+), as well as a composite combined endpoint. Periprocedural (<24 hours) clinical events, demographics, aneurysm characteristics and platelet aggregation (using P2Y12 reactivity unit, PRU) were analyzed.
Results
Treatment was performed with 19 FRED procedures in 18 patients with 19 aneurysms, and with 37 FRED X procedures in 35 patients harboring 40 aneurysms. Both groups achieved therapeutic preprocedural platelet inhibition by PRU testing. Intraprocedural thromboembolic events including intraluminal filling defects and side-branch slowing or loss occurred in 7/19 (36.8%) FRED and 0/37 FRED X procedures (P = 0.0002), with all being successfully recanalized using intra-arterial platelet inhibitors, without symptomatic ischemic or hemorrhagic events. The composite endpoint was reached in 11/19 (57.9%) FRED and 5/37 (13.5%) FRED X cases (P = 0.001), with multivariable analysis identifying device type (P = 0.015) among age, gender, and PRU.
Conclusions
The surface modification of the FRED X device may be associated with improved thrombogenic risk profile in our cohort, with elimination of intraprocedural thrombus formation and reduction of composite thromboembolic events.
Abstract as indexed in PubMed (PMID 41391599). Copyright the publisher.
Cite this paper
Snyder MH, Dincer A, Yu AJ, Burke SM, Ferraro T, Malek AM. X-Factor: Antithrombotic Coating Reduces Procedural Thromboembolic Events in Flow Redirection Endoluminal Device (FRED) Aneurysm Embolization. World Neurosurg 205:124723. 2026. doi:10.1016/j.wneu.2025.124723 PMID: 41391599.